GenAssist
Assisted Regeneration for Muscle Loss

Technology

 
 

MyoMatrix™

MyoMatrix™ is our patented flagship technology, a cutting-edge biomimetic designed to support and help heal areas with damaged muscle. MyoMatrix™ harnesses carefully selected proteins that mimic those naturally occurring in normal skeletal muscle. These proteins serve as a structural support system for muscle cells to reinforce the damaged muscle and support the growth of new muscle tissue.

The sleek design of MyoMatrix™ has several attractive features such as minimal preparation requirements, consistent and scalable manufacturing, and the ability to coax the remaining tissue to repair itself in a safe and non-toxic way. MyoMatrix™ is optimized for cellular infiltration, and over 3-4 weeks, it is replaced by the patient’s own muscle tissue. This dynamic process will not only reinforce muscle, but enhance strength, promote more effective physical therapy, and notably improve the well-being and happiness of the patient.

 

MyoSponge™

MyoSponge™ utilizes MyoMatrix™ technology in the form of an implantable, sponge-like scaffold for tissue repair. MyoSponge™ will be our first product used in the clinic. It is engineered to provide mechanical support to the wounded area and reinforce skeletal muscle tissue after severe muscle trauma. In animal models, MyoSponge™ implantation improved muscle structure and function.

MyoSponge™ will be most useful in severe traumatic injuries where surgery is required to reinforce muscle tissue. Examples include generalized Volumetric Muscle Loss from high-impact trauma, gunshot wounds, Type-III open fractures, and explosively formed projectiles. MyoSponge™ can also be used for the reinforcement of muscle in Compartment Syndrome, Necrotizing fasciitis, and muscle weakness caused by surgery.

 

MyoGel™

MyoGel™ is an injectable formulation of MyoMatrix™. MyoGel™ will be delivered in a pre-loaded syringe. After injection, MyoGel™ remains in a gel-like state at body temperature and can hold its shape once injected into the muscle. Since MyoGel™ is applied through a minimally invasive injection procedure, it can be used in a broad range of conditions where surgery would not be ideal.

The first clinical target for MyoGel™ will be pelvic floor disorders. Based on our conversations with Urogynecologists, MyoGel™ could be very useful in strengthening the pelvic floor to reduce the incidence of pelvic organ prolapse after childbirth. Other applications include athletic injuries and muscle atrophy from long-term immobility, bone fractures, old age, and Ozempic use.